Nang Kuang Pharmaceutical Co., Ltd. (TPE:1752)
Taiwan · Delayed Price · Currency is TWD 36.40
-0.05 (-0.14%)
Jan 22, 2026, 1:35 PM CST
Nang Kuang Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 2,224 | 2,200 | 2,150 | 1,940 | 1,780 | 1,755 | Upgrade | |
Revenue Growth (YoY) | 4.08% | 2.31% | 10.81% | 9.01% | 1.44% | -0.42% | Upgrade |
Cost of Revenue | 1,416 | 1,452 | 1,395 | 1,246 | 1,186 | 1,158 | Upgrade |
Gross Profit | 808.21 | 747.79 | 755.56 | 694.9 | 594.47 | 596.76 | Upgrade |
Selling, General & Admin | 293.68 | 270.88 | 252.78 | 227.29 | 204.05 | 211.74 | Upgrade |
Research & Development | 179.09 | 169.36 | 164.11 | 143.81 | 133.97 | 159.8 | Upgrade |
Operating Expenses | 472.67 | 437.57 | 495.72 | 373.24 | 339.99 | 371.81 | Upgrade |
Operating Income | 335.55 | 310.22 | 259.84 | 321.67 | 254.48 | 224.95 | Upgrade |
Interest Expense | -8.49 | -5.53 | -7.18 | -4.84 | -3.53 | -4.31 | Upgrade |
Interest & Investment Income | 2.8 | 3 | 10.64 | 2.69 | 3.46 | 4.21 | Upgrade |
Currency Exchange Gain (Loss) | 1.09 | 8.6 | 4.1 | 8.79 | -11.98 | -4.58 | Upgrade |
Other Non Operating Income (Expenses) | 9.23 | 9.82 | 9.44 | 9.25 | 10.04 | 11.7 | Upgrade |
EBT Excluding Unusual Items | 340.18 | 326.11 | 276.85 | 337.56 | 252.47 | 231.96 | Upgrade |
Gain (Loss) on Sale of Investments | -28.82 | -23.07 | -1.85 | 73.11 | 0.14 | -7.33 | Upgrade |
Gain (Loss) on Sale of Assets | -4.18 | 0.17 | 6.1 | -0.05 | -0.15 | - | Upgrade |
Legal Settlements | -0.37 | - | -67.43 | - | -22.96 | - | Upgrade |
Other Unusual Items | - | - | 0 | - | 5.26 | -1.02 | Upgrade |
Pretax Income | 306.82 | 303.2 | 213.68 | 410.63 | 234.76 | 223.61 | Upgrade |
Income Tax Expense | 49.75 | 59.8 | 15.27 | 58.63 | 38.65 | 40.21 | Upgrade |
Net Income | 257.07 | 243.41 | 198.41 | 352 | 196.11 | 183.4 | Upgrade |
Net Income to Common | 257.07 | 243.41 | 198.41 | 352 | 196.11 | 183.4 | Upgrade |
Net Income Growth | 110.46% | 22.68% | -43.63% | 79.49% | 6.93% | -15.66% | Upgrade |
Shares Outstanding (Basic) | 101 | 101 | 101 | 101 | 101 | 101 | Upgrade |
Shares Outstanding (Diluted) | 101 | 101 | 101 | 101 | 101 | 101 | Upgrade |
Shares Change (YoY) | 0.15% | 0.10% | -0.08% | -0.01% | 0.03% | 0.82% | Upgrade |
EPS (Basic) | 2.55 | 2.41 | 1.96 | 3.49 | 1.94 | 1.82 | Upgrade |
EPS (Diluted) | 2.54 | 2.40 | 1.96 | 3.48 | 1.94 | 1.81 | Upgrade |
EPS Growth | 109.99% | 22.45% | -43.68% | 79.38% | 7.18% | -16.59% | Upgrade |
Free Cash Flow | 1.96 | -58.17 | 45.1 | 275.35 | 400.58 | 60.87 | Upgrade |
Free Cash Flow Per Share | 0.02 | -0.57 | 0.45 | 2.72 | 3.96 | 0.60 | Upgrade |
Dividend Per Share | 1.600 | 1.600 | 2.000 | 2.300 | 1.800 | 1.600 | Upgrade |
Dividend Growth | -20.00% | -20.00% | -13.04% | 27.78% | 12.50% | -5.88% | Upgrade |
Gross Margin | 36.34% | 33.99% | 35.14% | 35.81% | 33.40% | 34.01% | Upgrade |
Operating Margin | 15.09% | 14.10% | 12.08% | 16.58% | 14.30% | 12.82% | Upgrade |
Profit Margin | 11.56% | 11.06% | 9.23% | 18.14% | 11.02% | 10.45% | Upgrade |
Free Cash Flow Margin | 0.09% | -2.64% | 2.10% | 14.19% | 22.50% | 3.47% | Upgrade |
EBITDA | 519.05 | 492.34 | 440.76 | 496.66 | 433.33 | 409.42 | Upgrade |
EBITDA Margin | 23.34% | 22.38% | 20.50% | 25.59% | 24.34% | 23.33% | Upgrade |
D&A For EBITDA | 183.5 | 182.12 | 180.92 | 174.99 | 178.85 | 184.47 | Upgrade |
EBIT | 335.55 | 310.22 | 259.84 | 321.67 | 254.48 | 224.95 | Upgrade |
EBIT Margin | 15.09% | 14.10% | 12.08% | 16.58% | 14.30% | 12.82% | Upgrade |
Effective Tax Rate | 16.21% | 19.72% | 7.15% | 14.28% | 16.46% | 17.98% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.